Bedrijfsoverzicht
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical entity dedicated to the identification, acquisition, development, and commercialization of novel therapeutic products specifically designed for the treatment of rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific regions. The company operates within the Healthcare sector, specifically under the Biotechnology industry, which implies a focus on high-risk, high-reward R&D-driven innovation rather than mature, cash-generative manufacturing. In terms of scale, the organization employs 1371 individuals and holds a market capitalization of $2.29 billion, reflecting its established presence in the specialized rare disease landscape. The annual revenue generated over the trailing twelve months stands at $673.00 million, a figure that positions Ultragenyx as a significant player in a niche market where total addressable markets are often constrained but pricing power can be substantial due to the critical nature of the treatments provided.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $673.00 million, yet this generated a net income of $-575,000,000, revealing a substantial gap between top-line growth and profitability that highlights a cost structure heavily weighted toward research, development, and commercialization expenses typical of early-stage biotech firms. Corresponding to this operational burn, the EBITDA for the period was $-500,000,000, while free cash flow stood at $-251,124,992, indicating that the company is currently utilizing its cash reserves to fund operations rather than generating surplus liquidity. The margin profile further illustrates these challenges, with a gross margin of -27.6%, an operating margin of -54.7%, and a profit margin of -85.4%, all of which indicate that the company is not yet profitable at the gross or operational levels and faces significant pressure to achieve economies of scale to improve bottom-line results. Regarding liquidity management, Ultragenyx holds $680.00 million in cash against total debt of $1.25 billion, creating a net debt position, although the debt-to-equity ratio is listed as N/A due to the negative equity structure inherent in these loss-making phases. The balance sheet is supported by a current ratio of 2.48, which suggests that the company maintains sufficient short-term assets to cover its short-term liabilities, providing a buffer despite the negative cash flow environment. Additionally, the return on equity is -608.5% and the return on assets is -22.0%, metrics that reveal management is currently utilizing shareholder capital and assets to fund growth initiatives rather than generating immediate financial returns, a common characteristic of biotechnology companies in the pre-commercialization or early commercialization stages.
Waarderingsbeoordeling
Valuation metrics for Ultragenyx present a complex picture, with a price-to-earnings ratio (TTM) listed as N/A because the company has not generated positive net income, while the forward P/E ratio is 287.97, a figure that implies the market is pricing in significant future earnings potential or is valuing the stock based on revenue and growth rather than current profitability. The price-to-book ratio is -28.07, a negative figure that indicates the company's market value is substantially below its book value, often seen in distressed or highly speculative biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 3.40 and the EV/EBITDA of -5.65 suggest that investors are valuing the company based on its revenue generation capabilities and pipeline value rather than current earnings power. In terms of trading range, the 52-week high is $42.37 and the 52-week low is $18.29; without a specific current price provided in the facts, the valuation must be interpreted relative to this established volatility band which spans a significant percentage difference between the high and low. The beta value of 0.25 indicates that the stock exhibits significantly lower volatility than the broader market, suggesting that the share price is less sensitive to general market movements and more driven by company-specific developments or sector-specific rare disease news.
Growth & Income
The company demonstrated a revenue growth rate of 25.9% year-over-year, whereas earnings growth is N/A due to the absence of positive earnings, implying that top-line expansion is currently decoupled from profitability and that any increase in revenue is being absorbed by high operational costs. As a non-dividend payer, Ultragenyx has a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company does not distribute profits to shareholders but instead retains all earnings to reinvest into research and development activities and to strengthen its balance sheet. This reinvestment strategy is essential for a biotechnology firm that must continuously fund clinical trials and regulatory approvals to advance its pipeline of novel products for rare genetic diseases. Consequently, the overall growth and income profile for Ultragenyx is characterized by strong top-line expansion funded entirely by internal cash reserves and external financing, with no current income generation for shareholders, reflecting a classic high-growth, cash-burning biotech investment thesis.